Melbourne, Australia, 01 May 2017: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases is pleased to announce it will present at the Association for Research in Vision and Ophthalmology (ARVO) annual scientific meeting next week.
OccuRx will present two separate posters at the conference that takes place next week from May 7th – 11th 2017 in Baltimore.
The first presentation is titled ‘The protective effect of OCX063 on reducing neovascularization and lesion size in a mouse model of choroidal neovascularization’. The presentation will highlight the effect of OCX063 has on choroidal neovascularization (CNV) in an experimental animal model. The results show that OCX063 reduced CNV lesion size and leakage at 7 days and 30 days and may provide an alternative treatment for wet age-related macular degeneration (AMD) patients especially those that do not respond to anti-VEGF therapies.
The second presentation is titled ‘OCX063, A Novel Small Molecule Drug, Exhibits Anti-Inflammatory and Anti-Fibrotic Properties in Retinal Cultures’. This presentation will highlight that OCX063 not only exerts anti-inflammatory effects on retinal microglia, but also has protective anti-inflammatory/anti-fibrotic effects on other cells, like Muller cells, which exhibit pathological phenotypes due to microglial activation. Thus, OCX063 may be a strategy for treating proliferative retinal diseases.
Professor Darren Kelly, Executive Chair of OccuRx said “We are delighted to have the opportunity to have two presentations at the ARVO event next week. Both studies showcase the effects of our novel small molecule drug OCX063 on CNV and anti-inflammatory effects in retinal microglia and other cells such as Muller cells.”
Paper publication references:
Erica L Fletcher; Alice A Brandli; Roy Kong; Fay Khong; Darren J. Kelly. “The protective effect of OCX063 on reducing neovascularization and lesion size in a mouse model of choroidal neovascularization.” Investigative Ophthalmology & Visual Science June 2017; 58(8):198
Roy Chze Khai Chze Khai Kong; Alison J Cox; Sylwia Glowacka; Darren J. Kelly; Fay Khong. “OCX063, A Novel Small Molecule Drug, Exhibits Anti-Inflammatory and Anti-Fibrotic Properties in Retinal Cultures.” Investigative Ophthalmology & Visual Science June 2017, Vol.58(8):1204
